Intrinsic Value Partners LLC lifted its position in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 32.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,371 shares of the company's stock after buying an additional 6,760 shares during the period. Moderna makes up about 3.2% of Intrinsic Value Partners LLC's investment portfolio, making the stock its 9th biggest position. Intrinsic Value Partners LLC's holdings in Moderna were worth $2,722,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently modified their holdings of MRNA. Raymond James & Associates grew its holdings in Moderna by 20.3% during the third quarter. Raymond James & Associates now owns 186,342 shares of the company's stock valued at $19,247,000 after purchasing an additional 31,423 shares during the period. Brown Advisory Inc. grew its holdings in Moderna by 88.3% during the third quarter. Brown Advisory Inc. now owns 6,142 shares of the company's stock valued at $634,000 after purchasing an additional 2,880 shares during the period. Mackenzie Financial Corp grew its holdings in Moderna by 3.2% during the third quarter. Mackenzie Financial Corp now owns 68,043 shares of the company's stock valued at $7,014,000 after purchasing an additional 2,135 shares during the period. IFM Investors Pty Ltd grew its holdings in Moderna by 4.6% during the third quarter. IFM Investors Pty Ltd now owns 65,752 shares of the company's stock valued at $6,792,000 after purchasing an additional 2,885 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Moderna by 18.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 409,423 shares of the company's stock valued at $42,289,000 after purchasing an additional 64,344 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on MRNA shares. HSBC restated a "reduce" rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. UBS Group boosted their price objective on Moderna from $143.00 to $151.00 and gave the company a "buy" rating in a research report on Tuesday. Oppenheimer boosted their price objective on Moderna from $142.00 to $163.00 and gave the company an "outperform" rating in a research report on Friday, May 3rd. William Blair reiterated a "market perform" rating on shares of Moderna in a research report on Monday, April 1st. Finally, Royal Bank of Canada boosted their target price on Moderna from $125.00 to $135.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $126.89.
Check Out Our Latest Stock Analysis on Moderna
Moderna Trading Down 4.4 %
Moderna stock traded down $5.38 during mid-day trading on Friday, hitting $117.31. The company's stock had a trading volume of 4,221,062 shares, compared to its average volume of 4,103,396. Moderna, Inc. has a one year low of $62.55 and a one year high of $142.79. The stock has a market cap of $44.96 billion, a PE ratio of -7.49 and a beta of 1.57. The company has a 50 day moving average of $107.65 and a 200-day moving average of $95.69. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.91 and a current ratio of 4.03.
Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. The company had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm's revenue was down 91.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.19 EPS. On average, research analysts anticipate that Moderna, Inc. will post -7.47 EPS for the current year.
Insider Activity
In other Moderna news, President Stephen Hoge sold 2,388 shares of the company's stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Shannon Thyme Klinger sold 544 shares of the business's stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the transaction, the insider now owns 9,267 shares of the company's stock, valued at $917,896.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, President Stephen Hoge sold 2,388 shares of the business's stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares of the company's stock, valued at approximately $143,358,473.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 154,954 shares of company stock valued at $16,647,776. Corporate insiders own 15.70% of the company's stock.
About Moderna
(
Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
